Remove Engineer Remove Hormones Remove Licensing
article thumbnail

Eneboparatide Advances in Hypoparathyroidism Trial: Key Phase III Update

XTalks

Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. AstraZeneca received eneboparatide during its $1.05 Without proper PTH function, patients may face kidney and bone complications.

Trials 59
article thumbnail

Adalvo signs licence deal with EQL Pharma for Mellozzan

Pharmaceutical Technology

Adalvo has entered a strategic licensing agreement with Swiss pharmaceutical company EQL Pharma for Mellozzan (melatonin) outside Europe and the US. Adalvo brings to the table its regulatory expertise and then will put its extensive commercial engine to work with a view of laying out a globalisation roadmap for Mellozzan.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

LegitScript Finds 1200 Percent Increase in Problematic Ads for Compounded GLP-1 Meds

XTalks

These advertisements, often found on social media platforms, search engines and various websites, frequently violate advertising guidelines and regulations. More than half a million individual ads referencing GLP-1s were monitored by LegitScript in just the last two months.

Pharmacy 104
article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

“Building on Pfizer’s established leadership position in breast cancer science and CDK 4/6 inhibition, we are excited to work with Arvinas to maximize ARV-471, the first PROTAC for breast cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer,” said Jeff Settleman, Ph.D.,

Protein 52
article thumbnail

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. Amolyt has also acquired an option to license the identified candidates for future clinical development.

In-Vivo 52
article thumbnail

Unblock My Hormones And Start Burning Fat TODAY With HB5

The Pharma Data

Product Name: Unblock My Hormones And Start Burning Fat TODAY With HB5. Click here to get Unblock My Hormones And Start Burning Fat TODAY With HB5 at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

article thumbnail

Pfizer Responds to Research Claims

Pfizer

In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.

Research 112